Research graph
References from Combination treatment of db/db mice with exendin‐4 and gastrin preserves β‐cell mass by stimulating β‐cell growth and differentiation. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1007/s001250051188
10.1007/s001250051188 · External reference
10.2337/diabetes.47.3.358
10.2337/diabetes.47.3.358 · External reference
10.1056/nejm199312303292703
10.1056/nejm199312303292703 · External reference
10.2337/diabetes.52.1.102
10.2337/diabetes.52.1.102 · External reference
10.1007/s00125-004-1336-4
10.1007/s00125-004-1336-4 · External reference
10.1038/nbt1115
10.1038/nbt1115 · External reference
10.1172/jci25764
10.1172/jci25764 · External reference
10.2337/diabetes.50.8.1720
10.2337/diabetes.50.8.1720 · External reference
10.2337/diacare.28.5.1092
10.2337/diacare.28.5.1092 · External reference
10.1007/s00125-005-1878-0
10.1007/s00125-005-1878-0 · External reference
10.1210/jc.2005-2220
10.1210/jc.2005-2220 · External reference
10.1007/s00125-005-1705-7
10.1007/s00125-005-1705-7 · External reference
10.1074/jbc.m209423200
10.1074/jbc.m209423200 · External reference
10.1007/s00125-002-0828-3
10.1007/s00125-002-0828-3 · External reference
10.2337/diabetes.48.12.2270
10.2337/diabetes.48.12.2270 · External reference
10.2337/diabetes.48.12.2358
10.2337/diabetes.48.12.2358 · External reference
10.2337/diabetes.53.11.2824
10.2337/diabetes.53.11.2824 · External reference
10.1016/s0016-5085(99)70292-1
10.1016/s0016-5085(99)70292-1 · External reference
10.1677/joe.0.1620167
10.1677/joe.0.1620167 · External reference
10.2337/diabetes.50.7.1571
10.2337/diabetes.50.7.1571 · External reference
10.1210/endo.139.4.5882
10.1210/endo.139.4.5882 · External reference
10.2337/diabetes.49.12.2021
10.2337/diabetes.49.12.2021 · External reference
10.1172/jci118591
10.1172/jci118591 · External reference
10.1074/jbc.m302684200
10.1074/jbc.m302684200 · External reference
10.2337/diabetes.54.9.2596
10.2337/diabetes.54.9.2596 · External reference
10.1007/s00125-003-1287-1
10.1007/s00125-003-1287-1 · External reference
10.1034/j.1600-0773.2002.910621.x
10.1034/j.1600-0773.2002.910621.x · External reference
10.1210/jc.2004-0761
10.1210/jc.2004-0761 · External reference
10.3727/096368908786092775
10.3727/096368908786092775 · External reference
10.2337/diabetes.52.1.124
10.2337/diabetes.52.1.124 · External reference
10.1074/jbc.m610482200
10.1074/jbc.m610482200 · External reference
10.1016/j.bbrc.2006.04.011
10.1016/j.bbrc.2006.04.011 · External reference
10.1016/j.cell.2007.12.015
10.1016/j.cell.2007.12.015 · External reference
10.1053/gast.2001.27998
10.1053/gast.2001.27998 · External reference
10.1016/s0021-9258(19)36565-2
10.1016/s0021-9258(19)36565-2 · External reference
10.2337/diacare.26.10.2929
10.2337/diacare.26.10.2929 · External reference
10.1677/joe.1.06480
10.1677/joe.1.06480 · External reference
10.1074/jbc.m508307200
10.1074/jbc.m508307200 · External reference
10.2337/diabetes.50.2007.s10
10.2337/diabetes.50.2007.s10 · External reference
10.1016/j.bbrc.2004.12.120
10.1016/j.bbrc.2004.12.120 · External reference
10.1038/36116
10.1038/36116 · External reference
10.1172/jci17645
10.1172/jci17645 · External reference
10.2337/diabetes.51.3.686
10.2337/diabetes.51.3.686 · External reference
Glucagon‐like peptide (GLP)‐2 reduces chemotherapy‐associated mortality and enhances cell survival in cells expressing a transfected GLP‐2 receptor
2001 · External reference
10.1038/nm1187
10.1038/nm1187 · External reference
10.2337/diabetes.53.6.1526
10.2337/diabetes.53.6.1526 · External reference
10.1152/ajpgi.2001.280.2.g298
10.1152/ajpgi.2001.280.2.g298 · External reference
10.1172/jci116708
10.1172/jci116708 · External reference
